273
Participants
Start Date
April 27, 2020
Primary Completion Date
March 30, 2022
Study Completion Date
November 28, 2022
GLP-1 receptor agonist
PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
Placebo
PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Central South University The Second Xiangya Hospital, Changsha
PegBio Co., Ltd.
OTHER